

Companies

Licensor

Licensee

Potential Use

Disease Area

Indication

Deal Financials

Potential Deal Size

Upfront

Milestones Total

Milestones Regulatory

Milestones Sales

Research Funding

Profit Sharing Licensor

Profit Sharing Licensee

Royalties

Equity

Compound

Compound Details

Compound Name

Development Stage

Territory

Year of Deal Establishment

Free Text Search

Filter Specification

119

OR

No.	Licensor	Potential Deal Size (mln) Amount	Upfront (mln) Remarks	Upfront (mln) Amount	Milestones total (mln) Remarks	Milestones total (mln) Amount	Milestones regulatory (mln) Remarks	Milestones regulatory (mln) Amount	Milestones sales (mln) Remarks	Milestones sales (mln) Amount	Research Funding (mln) Remarks	Research Funding (mln) Amount	Profit sharing Remarks	Profit sharing % licensor	Profit sharing % licensee	R %
033	ProStrakan Group	-	- including 2 year research funding	5.75	5.75 mln regulatory and sales-related milestones over 2 years including	140	-	-	-	-	- over 2 years including upfront	5.75	-	0	0	
034	Peregrine Pharmaceuticals (Technidone)	-	- as equity	1.3	-	18.7	start F II/III	1.7	-	-	-	0	-	0	0	
035	Peregrine Pharmaceuticals	-	-	0.25	-	16.5	-	16.5	-	0	-	0	-	0	0	
036	PDL Biopharma	-	-	30	-	680	-	480	-	200	-	0	USA	-	-	OL US